"Designing Growth Strategies is in our DNA"
The excess secretion of growth hormone by pituitary gland leads to a hormonal disorder called acromegaly. The symptoms of acromegaly include overgrowth of bone and cartilage which may lead to arthritis. The symptoms include joint aches, skin tags, headaches, enlarged lips, impaired vision, etc. Global prevalence of acromegaly was found to be 60 per million populations in 2017 and an incidence rate of 3-4 per million populations per year.
Current treatment of acromegaly includes surgery, medication, and radiation. Drugs like octreotide and lanreotide are being used to reduce excess growth hormone secretion. Drugs like cabergoline and bromocriptine are being used to lower the excess levels of growth hormone. Additionally, pegvisomant a drug which acts by blocking the action of growth hormone, is also in use for the treatment of acromegaly.
Pharmaceutical companies along with various research institutes have been focusing on studying and developing new treatment options for acromegaly. For instance; IONIS-GHR-LRx, which is being studied by Ionis Pharmaceuticals, Inc., is currently in phase-2 clinical trials for the study of safety, tolerability, and efficacy of IONIS-GHR-LRx patients with acromegaly.
To know how our report can help streamline your business, Speak to Analyst
At present around 70% of the pipeline candidates for acromegaly are in the phase-3 and phase-4 stage. More than half of the studies are sponsored by industry.
The report on ‘Acromegaly – Pipeline Review, 2020’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Acromegaly. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Acromegaly.
The report on ‘Acromegaly – Pipeline Review, 2020’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.
US +1 833 909 2966 ( Toll Free )